Collaboration, Licensing and Other Arrangements - Revenue Allocation (Detail) - Collaboration and License Agreement - United Therapeutics Corporation - USD ($)		1 Months Ended	9 Months Ended
		Jun. 30, 2021	Sep. 30, 2021	May 31, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price		$ 50,900,000		$ 50,200,000
R&D Services and License | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]	$ 18,400,000
Progress Measure		Ratably
Recognition Period		May 2021 - Oct 2021
Pre-Commercial Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]	$ 4,600,000
Progress Measure		Input
Recognition Period	[2]	% of completion of costs
Next-Gen R&D Services | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1]	$ 7,200,000
Progress Measure		Input
Recognition Period	[2]	% of completion of costs
Facility Expansion Services | Point In Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price	[1],[3]	$ 20,700,000
Recognition Period	[3],[4]	Transfer of control
Clinical Supplies
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 105,800,000
Clinical Supplies | R&D Services and License | Over Time
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total transaction price			$ 105,800
Allocation of Price			100.00%
Progress Measure			Ratably
Recognition Period	[5]		Sep 2018 - Dec 2021

[1] Allocation is based on management’s assessment of the stand-alone selling price of each performance obligation.

[2] Pre-Commercial Services and Next-Gen R&D Services performance obligations will be satisfied over time using the input method based on the costs incurred to date as a percentage of the total estimated costs to fulfill the contract. Incurred cost represents work performed, which corresponds with, and thereby best depicts, the transfer of control to the customer.

[3] The Company will also be acting as agent for the procurement of equipment for the manufacturing expansion for the UT Equipment. The $5.3 million received from UT for the UT Equipment was recognized as deposits from customer on the condensed consolidated balance sheet and will be released as the title is transferred to UT

[4] The Facility Expansion Services performance obligation would be recognized as control of manufactured products is transferred to the customer.

[5] Recognition period represents the estimated period to satisfy the performance obligation.